Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INM | US
0.05
21.04%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.29
0.23
0.35
0.23
InMed Pharmaceuticals Inc. a clinical stage pharmaceutical company develops a pipeline of prescription-based products. The company operates through two segments the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755 a cannabinol topical skin cream which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088 which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases including dermatology and ocular diseases. In addition it offers IntegraSyn an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene cannabicitran cannabidivarin and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver Canada.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
112.4%1 month
110.4%3 months
398.9%6 months
293.6%-
-
0.22
0.07
0.05
1.00
1.47
-
-7.91M
3.87M
3.87M
-
-156.58
-
-44.50
-72.09
0.09
1.05
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.16
Range1M
0.16
Range3M
0.66
Rel. volume
10.99
Price X volume
1.91M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
AquaBounty Technologies Inc | AQB | Biotechnology | 1.1 | 4.25M | -8.33% | n/a | 10.41% |
Titan Pharmaceuticals Inc | TTNP | Biotechnology | 4.58 | 4.19M | -4.38% | n/a | 0.00% |
NuCana plc | NCNA | Biotechnology | 1.86 | 4.18M | -1.06% | n/a | 0.00% |
Fresh America Corp | FRES | Biotechnology | 1.66 | 4.07M | -15.74% | n/a | 0.22% |
Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.4896 | 3.97M | -0.99% | n/a | 5.50% |
Windtree Therapeutics Inc | WINT | Biotechnology | 1.07 | 3.94M | 17.16% | n/a | 36.99% |
Genprex Inc | GNPX | Biotechnology | 1.51 | 3.91M | 265.62% | n/a | 0.00% |
Neurotrope Inc | NTRP | Biotechnology | 2.4 | 3.80M | 0.00% | n/a | 0.00% |
Gritstone Oncology Inc - Ordinary Shares | GRTS | Biotechnology | 0.0322 | 3.80M | -31.78% | n/a | 461.91% |
Sonnet BioTherapeutics Holdings Inc | SONN | Biotechnology | 5.71 | 3.71M | -3.38% | n/a | 5.74% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.00 | 0.53 | Expensive |
Ent. to Revenue | 1.47 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.22 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 398.90 | 72.80 | Riskier |
Debt to Equity | 0.07 | -1.23 | Expensive |
Debt to Assets | 0.05 | 0.25 | Cheaper |
Market Cap | 3.87M | 3.66B | Emerging |